
Drugs IPOs Depend o...


| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.27B | 2.61B | 2.82B | 2.65B |
| Cost of Sales | 1.25B | 1.41B | 1.80B | 1.79B |
| Gross Operating Profit | 992.13M | 1.17B | 986.84M | 831.82M |
| Selling, General, and Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Research & Development | n.a. | n.a. | n.a. | n.a. |
| Operating Income before D & A (EBITDA) | 992.13M | 1.17B | 986.84M | 831.82M |
| Depreciation & Amortization | 566.93M | 521.06M | 489.92M | 470.82M |
| Interest Income | 16.08M | 7.84M | 0.00 | 5.73M |
| Other Income - Net | -260.35M | -5.88M | -78.99M | -36.29M |
| Special Income / Charges | -382.98M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -202.04M | 650.34M | 417.93M | 330.44M |
| Interest Expense | 243.26M | 210.58M | 177.97M | 143.25M |
| Pre-Tax Income | -445.30M | 439.76M | 239.96M | 187.18M |
| Income Taxes | 103.54M | 103.82M | 999.84K | 14.33M |
| Minority Interest | 37.19M | 37.22M | 20.00M | 0.00 |
| Net Income From Continuing Operations | -548.84M | 335.95M | 239.96M | 172.86M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -548.84M | 335.95M | 239.96M | 172.86M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -586.03M | 298.73M | 218.96M | 172.86M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-165.86M | 335.95M | 239.96M | 172.86M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -580.00M | 321.25M | 238.96M | 172.86M |
| Basic EPS from Continuing Ops. | -2.62 | 1.28 | 1.00 | 0.86 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -2.62 | 1.28 | 1.00 | 0.86 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -2.62 | 1.28 | 1.00 | 0.86 |
| Basic Normalized Net Income/Share | -0.79 | 1.28 | 1.00 | 0.86 |
| EPS fr Continuing Ops. | -2.62 | 1.28 | 1.00 | 0.86 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -2.62 | 1.28 | 1.00 | 0.86 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -2.62 | 1.28 | 1.00 | 0.86 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.79 | 1.28 | 1.00 | 0.86 |
| Dividends Paid per Share | 1.16 | 1.17 | 1.11 | 1.03 |